CD25⁺ B-1a Cells Express Aicda

Hiroaki Kaku1*†‡, Nichol E. Holodick1‡, Joseph R. Tumang2† and Thomas L. Rothstein1,3,4†

1Center for Oncology and Cell Biology, The Feinstein Institute for Medical Research, Manhasset, NY, United States, 2Compass Therapeutics LLC, Cambridge, MA, United States, 3Department of Medicine, The Hofstra Northwell School of Medicine, Manhasset, NY, United States, 4Department of Molecular Medicine, The Hofstra Northwell School of Medicine, Manhasset, NY, United States

B-1a cells are innate-like B-lymphocytes producing natural antibodies. Activation-induced cytidine deaminase (AID), a product of the Aicda gene, plays a central role in class-switch recombination and somatic hypermutation in B cells. Although a role for Aicda in B-1a cells has been suggested on the basis of experiments with knock out (KO) mice, whether B-1a cells express Aicda, and if so, which B-1a cell subpopulation expresses Aicda, remains unknown. Here, we demonstrate that B-1 cells express Aicda, but at a level below that expressed by germinal center (GC) B cells. We previously reported that B-1a cells can be subdivided based on CD25 expression. We show here that B-1a cell Aicda expression is concentrated in the CD25⁺ B-1a cell subpopulation. These results suggest the possibility that previous studies of memory B cells identified on the basis of Aicda expression may have inadvertently included an unknown number of CD25⁺ B-1a cells. Although B-1a cells develop normally in the absence of Aicda, a competitive reconstitution assay reveals enhanced vigor for AID KO B-1a cell bone marrow (BM) progenitors, as compared with wild-type BM B-1 cell progenitors. These results suggest that AID inhibits the development of B-1a cells from BM B-1 cell progenitors in a competitive environment.

Keywords: AID, B-1a cells, CD25, B-1 cell subset, peritoneal cavity

INTRODUCTION

B-1 cells are innate-like B-lymphocytes that spontaneously and constitutively produce natural antibodies, which provide immediate protection against infection and rapid removal of dying cell debris (1, 2). Mouse B-1 cells are distinguished from B-2 cells both by phenotype and by function (3). Phenotypically, B-1 cells are characterized as IgM⁺, IgD⁺, B220⁺, CD23⁻, and CD43⁺ (and CD11b⁻ in the peritoneal cavity) (3). B-1 cells are either CD5⁺ (B-1a) or CD5⁻ (B-1b). Recent studies have shown B-1 cells can be further subdivided based on the expression of CD25 (4), CD73 (5), PD-L2 (CD273) (6–9), or ENPP1 (PC1) (10), suggesting different roles for each subpopulation.

Activation-induced cytidine deaminase (AID) plays a central role in class-switch recombination and somatic hypermutation (11). AID is expressed abundantly in germinal center (GC) B cells (12) and at a low level in immature B cells (13–15). It was recently reported that B-1 cells accumulate immunoglobulin somatic hypermutation and increase class switching from 1 week of age up to 6 months of age, and these changes are diminished in the absence of AID (16). Nonetheless, AID expression in B-1 cells has not been documented and is yet to be directly addressed, raising the possibility that B-1 cell changes in AID KO mice may represent indirect effects.

We previously found that expression of CD25 on B-1a cells is activation dependent and these CD25⁺ B-1a cells express leukemia inhibitory factor receptor as well as increased levels of activated STAT3 as compared to CD25⁻ B-1a cells (4). We explored the possibility that B-1 cells express AID...
and found that AID is expressed in B-1a cells and that this expression is concentrated in the activated, CD25+ B-1a cell pool.

**MATERIALS AND METHODS**

**Mice**

Male BALB/c-ByJ and C57BL/6 mice were obtained from The Jackson Laboratory at 6–8 weeks of age. CB17-SCID or CB17 mice of 6–8 weeks of age were obtained from Taconic. AID KO mice on a BALB/c background were obtained from Dr. Michel Nussenzweig with Dr. Tasuku Honjo’s permission. All mice were used for experimentation at 8–14 weeks of age. All studies were approved by the Institutional Animal Care and Use Committee at the Feinstein Institute for Medical Research. Mice were cared for and handled in accordance with the National Institutes of Health and institutional guidelines.

**Cell Purification and Flow Cytometry**

Peritoneal washout cells and splenocytes were obtained from 8- to 14-week-old wild-type (WT) or AID knock out (KO) mice and were stained with fluorescence-labeled antibodies to B220, CD5, CD25, CD23, and GL-7 and with peanut agglutinin (PNA). B-cell populations (peritoneal B-1a cells: B220+/CD5+, peritoneal CD25+ B-1a cells: B220+/CD5+CD25+, peritoneal CD25− B-1a cells: B220+/CD5−CD25+, splenic B2 cells: B220+/CD5−CD23+, or GC B cells: B220+/GL-7+/PNA(high)) were isolated using the Influx cell sorter (BD Biosciences). Post-sort, reanalysis of the B-cell populations showed them to be ≥98% pure. Cells were blocked with rat anti-mouse CD16/CD32 antibody (clone 2.4G2), stained with immunofluorescent antibodies, and then analyzed on a FACSCalibur flow cytometer (BD Biosciences) with appropriate gating. Images were constructed with FlowJo 6.0 software (Tree Star). PE-conjugated rat anti-mouse CD25 (clone PC61) was obtained from BD Pharmingen. The following antibodies were obtained from Biolegend: perCP-Cy5.5-conjugated rat anti-mouse CD45R/B220 (clone RA3-6B2); Alexa 647-conjugated rat anti-mouse CD5 (clone 53-7.3); and Alexa 647-conjugated rat anti-mouse GL-7. FITC-PNA was obtained from Sigma. CD23-PE-Cy7 (clone 2G8) was obtained from Abcam.

**Gene Expression**

Gene expression was assayed by real-time PCR as previously described (17). Briefly, RNA was prepared from B cells using the RNeasy mini kit (Qiagen), according to the manufacturer’s instructions. cDNA was prepared using avian myeloblastosis virus reverse transcriptase (Bio-Rad). Gene expression was then measured by real-time PCR using iQ SYBR Green (Bio-Rad) and normalized with β2-microglobulin. The following primer sets were used: β2-microglobulin (F-CCCAGGCTACATTGAAATCC/R-GCGTATGTACGTTCACGG); AID (AGAAAGTCAGCTGGAGACC/CTCCCTCTCACCAGCTAGCA). Gene expression was also measured by real-time PCR using TaqMan chemistry. Primer and probe sets were obtained from Applied Biosystems for Aicda (Mm01184115_m1) and β-actin, which was used for normalization.

**Adoptive Transfer**

Bone marrow (BM) was obtained from 2-month-old BALB/c-ByJ (IgM+) and 2-month-old CB17 mice (IgM−). BM B-1a cell progenitors (lineage negative, CD19+B220−/AA4.1+) were sort-purified using the Influx cell sorter (BD Biosciences), washed twice in 1× PBS, resuspended in 1× PBS, and then injected (i.v.) into recipient CB17-SCID mice at 0.6 × 106 cells per mouse in 0.2 ml. Recipient mice were not irradiated prior to transfer. Serum samples, spleens, and peritoneal washout cells were collected from euthanized CB17-SCID recipients 6 weeks post transfer.

**Statistics**

Comparisons were conducted between WT and AID KO mice using Graphpad Prism 6.0 with two-tailed tests as indicated in the figure legends.

**RESULTS**

**B-1a Cells Express Aicda and Gene Expression Is Restricted to the CD25+ B-1a Cell Subset**

The expression level of Aicda was evaluated in sort-purified peritoneal B-1a cells, peritoneal CD25+ B-1a cells (4), peritoneal CD25− B-1a cells, splenic B2 cells, and GC B cells from unmanipulated mice. The sorting strategy for isolating these populations is shown in Figure 1A. GC B cells displayed a high level of Aicda expression, which is consistent with previous reports (12), in contrast to splenic B-2 cells that expressed very little Aicda. We found that peritoneal B-1a cells expressed more Aicda than that by splenic B-2 cells, but less than that by GC B cells (Figure 1B). We then examined CD25+ B-1a cells in comparison to CD25− B-1a cells and found that CD25+ B-1a cells demonstrated a higher level of Aicda expression than did CD25− B-1a cells, total B-1a cells, and splenic B-2 cells, although this was still less than the level expressed by GC B cells. These results were confirmed using Taqman primers and probe (Figure S1 in Supplementary Material). Peritoneal CD25+ B-1a cells from C57BL/6 mice were also found to express Aicda in greater amounts than that by CD25− B-1a cells (Figure S2 in Supplementary Material). The mean level of Aicda expression in BALB/c CD25+ B-1a cells was 18-fold more than that of splenic B-2 cells but 40-fold less than that of GC B cells. Thus, B-1a cells, especially CD25+ B-1a cells, express Aicda.

**The Number of CD25+ B-1a Cells Is Unchanged in AID KO**

Mice lacking the AID gene on the BALB/c background were assessed for numbers of total peritoneal cells, total peritoneal lymphocytes, B-1a cells, CD25+ B-1a cells, and CD25− B-1a cells. There was no significant difference in the total number of peritoneal lymphocytes in AID KO mice (4.3 × 107 ± 0.71) compared to that in WT mice (3.0 × 107 ± 0.17) (Figure 2A), although the total number of cells in the peritoneal cavities of AID KO mice was greater than the number in WT mice, presumably due to
Figu 1 | Aicda gene expression in B cells. Peritoneal washout cells and spleen cells were obtained from 3-month-old BALB/c-ByJ mice, immunofluorescently stained, and sorted for peritoneal B-1a (B220<sup>lo</sup>CD5<sup>+</sup>), CD25<sup>+</sup> B-1a (B220<sup>lo</sup>CD5<sup>+</sup>CD25<sup>+</sup>), CD25<sup>−</sup> B-1a (B220<sup>lo</sup>CD5<sup>+</sup>CD25<sup>−</sup>), splenic B2 (B220<sup>+</sup>CD5<sup>−</sup>CD23<sup>+</sup>), and germinal center (GC, B220<sup>+</sup>GL-7<sup>+</sup>PNA<sup>hi</sup>) cells. The sorting strategy for these populations is shown in (A). RNA was prepared from each sort-purified B cell subset and reverse transcribed. (A) The level of Aicda relative to β<sub>2</sub>-microglobulin was determined by real-time PCR (SYBR Green) with the primers described in Section “Materials and Methods.” The means of three independent experiments are shown in (B), along with lines indicating SEMs.

AID Impairs BM B-1a Cell Development

It has been previously shown that Aicda deficiency impairs B-cell development (13); however, it is unknown whether this effect extends to B-1a cell development. To directly test the extent to which Aicda affects B-1a cell development, we set up a mixed chimera system. Figure 3A illustrates the experimental design, which involved adoptive transfer of B-1 cell-specific progenitors (Lin<sup>−</sup>B220<sup>hi</sup>-CD19<sup>+</sup>AA4.1<sup>+</sup>) obtained from the BM of AID KO
On the other hand, there was no difference in the percent of individual contributions of WT (IgMb)- and AID KO (IgMa)-derived (IgMa) and CB17 (IgMb) mice were used to assess the identity of CB17 WT mice. Allotypic differences between BALB/c-ByJ injected with 600,000 B-1-specific progenitors from the BM of CB17 WT mice; (2) SCID mice from the BM of BALB/c AID KO mice plus 600,000 B-1-specific progenitors from both WT mice. Three groups of chimera mice were set up: (1) SCID mice were injected with 600,000 B-1-specific progenitors from the BM of CB17 WT mice, (2) SCID mice were injected with 600,000 B-1-specific progenitors from the BM of BALB/c AID KO mice; and (3) SCID mice were injected with 600,000 B-1-specific progenitors from the BM of CB17 WT mice. Allotypic differences between BALB/c-ByJ (IgMβ) and CB17 (IgMβ) mice were used to assess the individual contributions of WT (IgMβ)- and AID KO (IgMβ)-derived B-1a cells to the B-1a cell pool.

We first examined the percent of total lymphocytes in the peritoneal washouts that were either IgM4+ or IgM5+. Interestingly, in the chimera mice receiving B-1 cell progenitors from both AID KO and WT BM, there were more AID KO-derived (IgM4+) B cells than WT-derived (IgM5+) B cells (p = 0.01) (Figure 3A). On the other hand, there was no difference in the percent of IgM4+ or IgM5+ lymphocytes that were peritoneal B-1a cells (Figure 3B) in mice receiving B-1 cell progenitors from both AID KO and WT BM. Thus, the total number of peritoneal B-1a cells derived from WT BM B-1 cell progenitors was significantly lower than those derived from AID KO BM B-1 cell progenitors (p = 0.01) (Figure 3C). As a control, BM B-1 cell progenitors from WT mice or AID KO mice were transferred alone into SCID recipients to detect any differences in reconstitution when the progenitors from these two sources (BALB/c or CD17 mice) were transferred alone. The results of the single transfers demonstrated no significant differences in the overall reconstitution of WT or AID KO mouse B-1 cell progenitors when transferred individually (Figures 3A–C). Together, these results demonstrate that Aicda inhibits the development of B-1a cells from BM B-1 cell progenitors in a competitive environment.

**DISCUSSION**

We found that B-1a cells, particularly CD25+ B-1a cells, express Aicda. This Aicda expression occurs in the absence of intentional stimulation and without participation in GCs. Our results support the findings of Herzenberg and colleagues regarding the loss of somatic mutation and isotype switching from B-1 cell immunoglobulin in the absence of AID (16). Thus, we have extended previously reported functional results by directly demonstrating that WT B-1a cells express Aicda, and we have shown that Aicda expression is concentrated within the CD25+ B-1a cell subpopulation.

Recent studies have utilized AID reporter constructs to identify memory B cells that developed in GCs. In some systems, AID expression appears to impact viability. Immature murine B cells express AID and AID-deficient immature B cells are more resistant to apoptosis than immature B cells that express AID (15). Moreover, AID-deficient GC B cells are more resistant to apoptosis (22). These data suggest a role for AID in regulating cell viability. Along these lines, we found more B-1 cells in the peritoneal cavities of SCID mice after reconstitution with AID KO B-1 progenitor cells, and this was accentuated in BM chimeras wherein competition exists between WT and KO B-1 cell progenitors. Thus, AID is likely involved in the development and/or viability of B-1a cells.

The phenotype of mouse-like human B-1 cells has recently been redefined (23) from its previous focus on CD5 (24), an unreliable marker for B-1 cells in *Homo sapiens* and other species (25–27). It has been reported that AID-deficient hyper IgM syndrome patients are prone to develop autoimmune or inflammatory diseases such as diabetes mellitus, polyarthritis, autoimmune hepatitis, hemolytic anemia, and immune thrombocytopenia...
Our results suggest that B-1 cells should be considered as the pathogenesis of AID-deficient autoimmunity is probed.

**AUTHOR CONTRIBUTIONS**

HK, NH, and JT designed and performed the research, analyzed and interpreted data, and wrote the manuscript; TR interpreted data and wrote the manuscript.

**FUNDING**

This work was supported by Public Health Service grant AI029690 awarded to TR by the National Institutes of Health.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00672/full#supplementary-material.
REFERENCES

1. Rothstein TL, Griffin DO, Holodick NE, Quach TD, Kaku H. Human B-1 cells take the stage. Ann N Y Acad Sci (2013) 1285:97–114. doi:10.1111/nyas.12137

2. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A (2000) 97(3):1184–9. doi:10.1073/pnas.113184

3. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol (2011) 11(1):34–46. doi:10.1038/nri2901

4. Tumang JR, Holodick NE, Vizconde TC, Kaku H, Frances R, Rothstein TL. A CD25(+) positive population of activated B1 cells expresses LIFR and responds to LIF. Front Immunol (2011) 2.6. doi:10.3389/fimmu.2011.00006

5. Kaku H, Cheng KF, Al-Abed Y, Rothstein TL. A novel mechanism of B-cell-mediated immune suppression through CD73 expression and adenosine production. J Immunol (2014) 193(2):5904–13. doi:10.4049/jimmunol.1400336

6. Zhong X, Tumang JR, Gao W, Bai C, Rothstein TL. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol (2007) 37(9):2405–10. doi:10.1002/eji.200737461

7. Zhong X, Lau S, Bai C, Degauque N, Holodick NE, Steven SJ, et al. A novel subpopulation of B-1 cells is enriched with autoreactivity in normal and lupus-prone mice. Arthritis Rheum (2009) 60(12):3734–43. doi:10.1002/art.25015

8. Kaku H, Rothstein TL. Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells. Through lineage-specific activity of a unique, intronic promoter. Genes Immun (2010) 11(1):55–66. doi:10.1038/genie.2009.68

9. Zhong X, Rothstein TL. LP2B1: a new player in autoimmunity. Mol Immunol (2011) 48(11):1292–300. doi:10.1016/j.molimm.2010.12.006

10. Wang H, Shin DM, Abbasi S, Jain S, Kovalchuk AL, Beaty N, et al. Expression of plasma cell alloantigen 1 defines layered development of B-1 cells. J Immunol (2011) 187(2):679–89. doi:10.4049/jimmunol.1000336

11. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class Switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 102(5):553–63. doi:10.1016/S0092-8674(00)00787-7

12. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem (1999) 274(26):18470–6. doi:10.1074/jbc.274.26.18470

13. Kuraoka M, Holl TM, Liao D, Womble M, Cain DW, Reynolds AE, et al. Activation-induced cytidine deaminase mediates central tolerance in B cells. Proc Natl Acad Sci U S A (2011) 108(28):11560–5. doi:10.1073/pnas.1102571108

14. Kuraoka M, McWilliams L, Kelsoe G. AID expression during B-cell development: searching for answers. Immuno Rev (2011) 245(1):3–13. doi:10.1111/j.1600-065X.2011.01009.x

15. Kuraoka M, Kelsoe G. A novel role for activation-induced cytidine deaminase: central B-cell tolerance. Cell Cycle (2011) 10(20):3423–4. doi:10.4161/cc.20.10.17693

16. Yang Y, Wang C, Yang Q, Kantor AB, Chu H, Ghosn EE, et al. Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires. Elife (2015) 4:e09083. doi:10.7554/eLife.09083

17. Tumang JR, Frances R, Yeo SG, Rothstein TL. Cutting edge: spontaneously Ig-secreting B-1 cells violate the accepted paradigm for expression of differentiation-associated transcription factors. J Immunol (2005) 174(6):3173–7. doi:10.4049/jimmunol.174.6.3173

18. Crouch EE, Li Z, Takizawa M, Fichtner-Feigl S, Gourzi P, Montano C, et al. Regulation of AID expression in the immune response. J Exp Med (2007) 204(5):1145–56. doi:10.1084/jem.20061952

19. Mullins CD, Su MY, Huchtagowder V, Chu L, Lu I, Kulkarni S, et al. Germline center B-cells resist transformation by Kras independently of tumor suppressor Arf. PLoS One (2013) 8(6):e67941. doi:10.1371/journal.pone.0067941

20. Healy JA, Nugent A, Rempel RE, Moffitt AB, Davis NS, Jiang X, et al. GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo. Blood (2016) 127(22):2723–31. doi:10.1182/blood-2015-07-659938

21. Yang Y, Ghosn EE, Cole LE, Obukhanych P, Vogel SN, et al. Antigen-specific memory in B-1a and its relationship to natural immunity. Proc Natl Acad Sci U S A (2012) 109(14):5388–93. doi:10.1073/pnas.1121627109

22. Bouilanne B, Rojas OL, Haddad D, Zaheen A, Kapelnikov A, Nguyen T, et al. AID and caspase 8 shape the germinal center response through apoptosis. J Immunol (2013) 191(12):5840–7. doi:10.4049/jimmunol.1301776

23. Quach TD, Rodriguez-Zahrbenko N, Hopkins TJ, Guo X, Hernandez AM, Li W, et al. Distinctions among circulating antibody-secreting cell populations, including B-1 cells, in human adult peripheral blood. J Immunol (2016) 196(3):1006–9. doi:10.4049/jimmunol.1501843

24. Casali P, Notkins AL. Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. Annu Rev Immunol (1988) 7:513–35. doi:10.1146/annurev.immunol.07.040189.002501

25. Freedman AS, Freeman G, Whitman J, Segil J, Daley J, Levine H, et al. Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol (1989) 19(5):849–55. doi:10.1002/eji.1801989511

26. Raman C, Knight KL. CD5+ B cells predominate in peripheral tissues of rabbit. J Immunol (1992) 149(12):3858–64.

27. Guelpa-Fonlupt V, Tonnelle C, Blaise D, Fougereau M, Fumoux F. Discrete early pro-B and pre-B stages in normal human bone marrow as defined by surface pseudo-light chain expression. Eur J Immunol (1994) 24(1):257–64. doi:10.1002/eji.180240140

28. Jesus AA, Duarte AJ, Oliveira JR. Autoimmunity in hyper-IgM syndrome. J Clin Immunol (2008) 28(Suppl 1):S62–6. doi:10.1007/s10875-008-9171-x

29. Meyers G, Ng YS, Fichtner-Feigl S, Montano C, Gourzi P, Fagarasan S, et al. Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans. Proc Natl Acad Sci U S A (2011) 108(28):11554–9. doi:10.1073/pnas.1102600108

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Kaku, Holodick, Tumang and Rothstein. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.